SCHEMBL27403256

SCHEMBL27403256

COc1ccc(F)c(F)c1C(C)(C)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46
AKR1C3 P42330 2/20 0.42
AKR1C2 P52895 2/20 0.42
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR2A P28223 2/20 0.39
HTR2C P28335 2/20 0.39
HTR2B P41595 2/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22655993 0.83 CES2 (0.45) AKR1C3AKR1C2MEN1ALDH1A1KMT2A
SCHEMBL31691805 0.83 CES2 (0.45) AKR1C3AKR1C2MEN1ALDH1A1KMT2A
SCHEMBL10300148 0.79 HTR2A (0.41) HTTLMNAMAPK1RAB9AMEN1
SCHEMBL13748809 0.79 HTR2A (0.44) HTTLMNAMAPK1RAB9AHTR2A
SCHEMBL27403240 0.79 PTGDR2 (0.42) HTTLMNARAB9AMEN1ALDH1A1
SCHEMBL27403233 0.77 RIPK1 (0.40) AKR1C3AKR1C2L3MBTL1CES2CES1
SCHEMBL29114193 0.76 HTR2A (0.40) HTTLMNAMAPK1RAB9AMEN1
SCHEMBL19469457 0.76 AKR1C3 (0.61) HTTLMNAMAPK1RAB9AAKR1C3
SCHEMBL31447104 0.76 AKR1C3 (0.40) HTTLMNAMAPK1RAB9AAKR1C3
SCHEMBL603406 0.76 AKR1C3 (0.57) HTTLMNAMAPK1RAB9AAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642782-A2 ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF Pliant Therapeutics, Inc. (US) 2025-11-05 EP disclosed
US-20240245682-A1 ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF PLIANT THERAPEUTICS, INC. 2024-07-25 US disclosed
WO-2024145245-A2 ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2024-07-04 WO disclosed
WO-2024145245-A2 ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2024-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245682-A1 ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF ITGB8, ITGAV, ITGA8 HTT 4809/4885LMNA 1775/4885MAPK1 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.